Beam Therapeutics Inc. — Director's Dealing 2021

Dec 24, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Beam Therapeutics Inc. (BEAM)
CIK: 0001745999
Period of Report: 2021-12-22

Reporting Person: Ciaramella Giuseppe (President & CSO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-22	Common Stock	M	2607	$7.22	Acquired	65380	Direct
2021-12-22	Common Stock	S	1216	$85.39	Disposed	64164	Direct
2021-12-22	Common Stock	S	1101	$86.62	Disposed	63063	Direct
2021-12-22	Common Stock	S	290	$87.34	Disposed	62773	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-22	Stock Option (Right to Buy)	$7.22	M	2607	Disposed	2029-05-17	Common Stock (2607)	Direct

Footnotes

F1: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.

F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.00 to $85.88, inclusive.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.15 to $86.99, inclusive.

F5: The option vests as to 25% on the first anniversary of the of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested.